ライフサイエンスコーパス: subunit vaccine

1 protection of mice than that obtained with a subunit vaccine.

2 cacy, which may be important in its use as a subunit vaccine.

3 e search for potential components of a multi-subunit vaccine.

4 nts who received an A/Vietnam/1203/2004 H5N1 subunit vaccine.

5 successful immunization with a tuberculosis subunit vaccine.

6 topes for a much-needed S. aureus-protective subunit vaccine.

7 e antigenic responses elicited by a live and subunit vaccine.

8 oundation for the generation of a protective subunit vaccine.

9 on of the molecule might have potential as a subunit vaccine.

10 f Q fever preventatives such as an effective subunit vaccine.

11 of this organism to study its potential as a subunit vaccine.

12 reduce the size of an antigen protein for a subunit vaccine.

13 and thus is a strong candidate for a cholera subunit vaccine.

14 viding the basis for a novel T-cell targeted subunit vaccine.

15 active antigen candidate for a pediatric RSV subunit vaccine.

16 Adjuvants are central to the efficacy of subunit vaccines.

17 tems enable rapid and scalable production of subunit vaccines.

18 cellular immunity to gH and gL within future subunit vaccines.

19 egimens are recommended for all prophylactic subunit vaccines.

20 be possible to develop effective single-dose subunit vaccines.

21 igenic ORFs that may be useful components of subunit vaccines.

22 onsidered in the design of future Salmonella subunit vaccines.

23 es, including vectored, live attenuated, and subunit vaccines.

24 thus will guide rational design of MERS-CoV subunit vaccines.

25 taneously increase the potency and safety of subunit vaccines.

26 uired for the rational design of ricin toxin subunit vaccines.

27 serve as a potential candidate for MERS-CoV subunit vaccines.

28 r enhancing the T-cell responses elicited by subunit vaccines.

29 tive hosts for the synthesis and delivery of subunit vaccines.

30 entified 13 candidate Chlamydia proteins for subunit vaccines.

31 l pathogenesis and to develop anti-Chlamydia subunit vaccines.

32 e motility and for development of sporozoite subunit vaccines.

33 lamydial pathogenesis and the development of subunit vaccines.

34 portunities for production of more effective subunit vaccines.

35 und on DENV particle surfaces when designing subunit vaccines.

36 uvant effect of MF59 when combined with H5N1 subunit vaccines.

37 mplications for the design of future protein subunit vaccines.

38 enerated with live, attenuated strains or F1 subunit vaccines.

39 e useful for diagnostics and next-generation subunit vaccines.

40 for enhancing the immunogenicity of protein subunit vaccines.

41 for inclusion in future human orthopoxvirus subunit vaccines.

42 have proven more efficacious than killed or subunit vaccines.

43 structured flavivirus surface when designing subunit vaccines.

44 to substantially enhance humoral immunity to subunit vaccines.

45 for the development of safe and efficacious subunit vaccines, a direct comparison of the immunogenic

46 For subunit vaccines, adjuvants play a key role in shaping i

47 Booster vaccination with a subunit vaccine (Ag85B-ESAT-6+CAF01) expanded IL-2(+) CD

48 the leading candidate Ags for inclusion in a subunit vaccine against blood-stage malaria.

49 the known entry properties of BoNT/A, an HCR subunit vaccine against BoNT/A that contained the point

50 usion protein has significant potential as a subunit vaccine against BVDV infection.

51 Our results provide a path to a subunit vaccine against dengue virus and have implicatio

52 a protective immune response to a candidate subunit vaccine against DENV-2.

53 ne responses to a toxoid and fimbria-derived subunit vaccine against ETEC.

54 The results of a clinical trial of a subunit vaccine against genital herpes were recently rep

55 development in recent years, an efficacious subunit vaccine against Plasmodium falciparum remains to

56 c domain (pB5), an attractive component of a subunit vaccine against smallpox.

57 In the first phase 1 study of any candidate subunit vaccine against tuberculosis, recombinant modifi

58 the inclusion of CTB in the development of a subunit vaccine against V. cholerae.

59 to generate and evaluate recombinant protein subunit vaccines against C. burnetii To accomplish this,

60 analytic vaccinology for the development of subunit vaccines against complex pathogens.

61 way may provide a general delivery route for subunit vaccines against many mucosal pathogens.

62 utilize attenuated live virus as opposed to subunit vaccines against ocular HSV-1 infection.

63 s contrast with the utility of type IV pilin subunit vaccines against other infectious diseases and h

64 human T cell Ags suitable to be included in subunit vaccines against tuberculosis.

65 to facilitate the production and delivery of subunit vaccines against various pathogenic bacteria and

66 Although inactivated viruses and subunit vaccines alleviate many of these concerns, they

67 ombination is no more protective than either subunit vaccine alone.

68 t was not detected upon vaccination with the subunit vaccine alone.

69 site of S1 could be an attractive target for subunit vaccine and drug development.

70 nogenicity to a trivalent influenza seasonal subunit vaccine and to tetanus toxoid (TT) in mouse.

71 S enables rational design of next-generation subunit vaccines and functional and medicinal chemical i

72 implications for the design of CD8(+) T cell subunit vaccines and in particular raise the exciting pr

73 ne proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic a

74 HCI) is a crucial step in the development of subunit vaccines and prediction of such binding could gr

75 These materials should enable a range of subunit vaccines and provide new possibilities for thera

76 r a physiological route of inoculation and a subunit vaccine approach elicited MCMV-specific and prot

77 No subunit vaccine approach showed efficacy in mice followi

78 This is the first demonstration that a subunit vaccine approach to smallpox-monkeypox immunizat

79 5HA vaccine, which is based on a traditional subunit vaccine approach, HAd-H5HA vaccine induced a thr

80 Current subunit vaccine approaches do not provide efficient long

81 vaccine Dengvaxia has boosted the pursuit of subunit vaccine approaches, and nonstructural protein 1

82 iven their admirable safety records, protein subunit vaccines are attractive for widespread immunizat

83 Recombinant subunit vaccines are easier to manufacture with a relati

84 Current subunit vaccines are incapable of inducing Ag-specific C

85 Antigens in modern subunit vaccines are largely soluble and poorly immunoge

86 cines, tetravalent DENV envelope (E) protein subunit vaccines are likely to stimulate balanced immune

87 to increase adaptive responses to influenza subunit vaccines are not well characterized.

88 Subunit vaccines are often less immunogenic than whole p

89 Heat-inactivated formulations and subunit vaccines are safer but less potent and require a

90 hat additional control strategies, such as a subunit vaccine, are required to block transmission and

91 the utility of a newly developed recombinant subunit vaccine based on the HeV attachment (G) glycopro

92 evaluation of the efficacy of a recombinant subunit vaccine based on the RVFV Gn and Gc glycoprotein

93 inical trials in young women have shown that subunit vaccines based on human papillomavirus (HPV) 16

94 This Review examines prophylactic HPV subunit vaccines based on the ability of the viral L1 ca

95 Subunit vaccines based on the herpes simplex virus 2 (HS

96 Therapeutic subunit vaccines based on tumor-associated antigens (TAA

97 murium are potentially useful for developing subunit vaccines because of high immunogenicity and prot

98 ting of a threatened pandemic before matched subunit vaccines become available.

99 ous mucosal priming followed by a parenteral subunit vaccine booster paves the way for clinical trial

100 ditary hemochromatosis may be protected with subunit vaccines but should not be exposed to live-atten

101 ant molecules have been developed to enhance subunit vaccines, but in general these materials have fa

102 We have previously created a subunit vaccine by encapsulating a recombinant coccidioi

103 s strategy to optimize a rPfMSP2 (3D7)-based subunit vaccine by producing unfused rPfMSP2 or chimeric

104 re, the gC-2 subunit antigen enhances a gD-2 subunit vaccine by stimulating a CD4+ T-cell response, b

105 easibility of producing safe and inexpensive subunit vaccines by using plant production systems.

106 Therefore, the intrinsic limitation of subunit vaccines can be overcome through shielding these

107 ether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable imm

108 ese results suggest that FspA1 may be a good subunit vaccine candidate against C. jejuni disease.

109 d subcutaneously with the glycoprotein-based subunit vaccine candidate and then subjected to heterolo

110 genesis and potentially optimizing Pgp3 as a subunit vaccine candidate antigen.

111 RH5 is a leading subunit vaccine candidate because anti-RH5 antibodies in

112 d varicella-zoster virus glycoprotein E (gE) subunit vaccine candidate for herpes zoster is in develo

113 cine production systems to generate a dengue subunit vaccine candidate in tobacco.

114 IKV envelope protein domain III (EDIII) is a subunit vaccine candidate with cross-neutralization acti

115 otein generated in this study is a promising subunit vaccine candidate with high efficacy in preventi

116 YopB/LcrV+dmLT is a promising subunit vaccine candidate with the potential to elicit b

117 ke conformation and is a potential prefusion subunit vaccine candidate.

118 litate the selection of promising chlamydial subunit vaccine candidates for further evaluation.

119 ecific glycan analysis of one of the leading subunit vaccine candidates from Novavax, which is based

120 nated by the subunit approach; however, many subunit vaccine candidates have had limited efficacy in

121 stability of previous RSV fusion protein (F) subunit vaccine candidates have hampered vaccine develop

122 Inclusion of multiple Ag variants in subunit vaccine candidates is one strategy that has aime

123 model, as suboptimal dosing of several RSV F subunit vaccine candidates led to the priming for ERD.

124 Most subunit vaccine candidates tested in clinical trials hav

125 n this study, we developed and evaluated two subunit vaccine candidates that consisted of the same pr

126 gens have become important components of the subunit vaccine candidates that we are currently develop

127 ea pig model of recurrent genital herpes, of subunit vaccine candidates that were based on eight reco

128 ea pig model of recurrent genital herpes, of subunit vaccine candidates that were based on eight reco

129 Live attenuated and subunit vaccine candidates, which are under clinical eva

130 OPS to facilitate the synthesis of glanders subunit vaccine candidates.

131 Recombinant subunit-vaccine candidates offer potential alternatives,

132 good road map for guiding the development of subunit vaccines capable of inducing the same.

133 that immunization with a licensed influenza subunit vaccine coated on metal microneedles can activat

134 ressed directly, it is a promising potential subunit vaccine component.

135 A subunit vaccine composed of protective vaccinia virus pr

136 We developed a subunit vaccine composed of the NAb targets gD and gB an

137 tilizing non-catalytic full-length BoNT or a subunit vaccine composed of the receptor binding domain

138 To overcome this issue, subunit vaccines composed of VV envelope proteins from b

139 s, have been mostly replaced by acellular or subunit vaccines composed of well-defined, purified anti

140 infection and use it in the evaluation of a subunit vaccine comprised of soluble G glycoprotein (sG)

141 Subunit vaccines comprised of glycoprotein D (gD-2) fail

142 Subunit vaccines consist of nongenetic components of the

143 s become important to the development of new subunit vaccines consisting of isolated antigens.

144 ne designs: artificially exposed surfaces of subunit vaccines contain epitopes unfavorable for vaccin

145 Many therapeutic proteins and protein subunit vaccines contain heterologous trimerization doma

146 ies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discord

147 ing a Th1 response and indicate that while a subunit vaccine containing the ML0276 protein may be use

148 e efficacies of two experimental vaccines, a subunit vaccine containing two recombinant outer membran

149 -2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycop

150 ction during species-specific outbreaks, but subunit vaccines containing broadly cross-protective ant

151 us immunization of C57BL/6 mice with protein subunit vaccines containing one or two of these lipoprot

152 (nonpigmented) strains and immunization with subunit vaccines containing recombinant low-calcium-resp

153 Subunit vaccines containing universal tumor associated a

154 suggests that a combination of CSP and TRAP subunit vaccines could enhance protection against malari

155 ectin epitopes to be studied in an amebiasis subunit vaccine designed to elicit mucosal immunity mimi

156 tudy, we revealed an intrinsic limitation of subunit vaccine designs: artificially exposed surfaces o

157 allenge with HSV-2 than that obtained with a subunit vaccine, despite inducing lower titers of HSV-2

158 accine design through attenuation as well as subunit vaccine development continue to move forward to

159 zing antibodies and potential candidates for subunit vaccine development, but our understanding of th

160 cs and transmission monitoring tools and for subunit vaccine development.

161 alizing antibodies, has become the focus for subunit vaccine development.

162 The advances in subunit vaccines development have intensified the search

163 ce interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% t

164 ed in clinical trials, the RR2 protein-based subunit vaccine elicited a significant reduction in viru

165 gue against inclusion of LppQ-N' in a future subunit vaccine for CBPP.

166 Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) dep

167 The development of a subunit vaccine for smallpox represents a potential stra

168 d a polyethylene glycol (PEG) hydrogel-based subunit vaccine for the delivery of an antigenic peptide

169 promising candidates for the development of subunit vaccines for immunization against melioidosis.

170 Development of subunit vaccines for malaria that elicit a strong, long-

171 ated or attenuated viral vaccines along with subunit vaccines for prophylaxis and treatment.

172 were immunized with H1N1/A/California/7/2009 subunit vaccines, formulated with different adjuvants in

173 n the mechanistic basis of the SA-4-1BBL/SVN subunit vaccine formulation in a lung carcinoma model an

174 factory immunogenicity suggest that such RBD subunit vaccine formulations hold great promise to comba

175 New subunit vaccine formulations with increased potency are

176 MF59-adjuvanted glycoprotein B (gB) protein subunit vaccine (gB/MF59) is the most efficacious vaccin

177 In the present study, a candidate subunit vaccine, GEN-003/MM-2, was evaluated for its abi

178 ing ZIKV infections in mice.IMPORTANCE Viral subunit vaccines generally show low efficacy.

179 ulmonary tuberculosis and vaccination with a subunit vaccine (H56) induced poor protection against it

180 edge, this is the first time a protein based subunit vaccine has been able to induce CD8+ T cell agai

181 ion against many infectious diseases, but no subunit vaccine has induced CD8(+) T cells that correlat

182 This is the first time a subunit vaccine has shown a significant reduction in ocu

183 osal immune system of the genital tract with subunit vaccines has failed to induce potent and durable

184 CS-based subunit vaccines have been hampered by suboptimal immuno

185 Subunit vaccines have been investigated in over 1000 cli

186 Previous human trials of subunit vaccines have been unsuccessful.

187 Subunit vaccines have failed, to date, to fully protect

188 However, E protein subunit vaccines have historically performed poorly, in

189 usly investigated as an adjuvant for protein subunit vaccines; here we optimize the CAFs for delivery

190 Here we provide an overview of subunit vaccine history as it pertains to instigating T

191 Zika subunit vaccines, however, have shown poor performance i

192 ion would be the development of an effective subunit vaccine; however, no approved vaccine currently

193 genicity and safety of an investigational HZ subunit vaccine (HZ/su).

194 rtain sF constructs could serve as potential subunit vaccine immunogens against henipaviruses and als

195 Success of the recombinant subunit vaccine in AGMs provides pivotal data in support

196 The success of this new subunit vaccine in nonhuman primates provides critical d

197 on; emphasizing the needs for studies of the subunit vaccine in PLWH.

198 he recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was

199 Despite the consistent failures of HSV subunit vaccines in clinical trials spanning the past 28

200 Current antiplague subunit vaccines in development for utilization in human

201 Our data suggest that a subunit vaccine incorporating bacterially expressed IMV-

202 cines present safety challenges, and protein subunit vaccines induce primarily antibody responses.

203 hereas vaccination of mice with an influenza subunit vaccine induced moderate virus-specific IgG1, va

204 Development of an antimalarial subunit vaccine inducing protective cytotoxic T lymphocy

205 Nanoparticle-based vaccines, including subunit vaccines involving synthetic and/or natural poly

206 ted recombinant varicella zoster virus (VZV) subunit vaccine is being developed for the prevention of

207 n ocular herpes simplex virus type 1 (HSV-1) subunit vaccine is the identification of an efficient, s

208 The glycoprotein B (gB) plus MF59 adjuvant subunit vaccine is the most efficacious tested clinicall

209 A subunit vaccine is the only option in the absence of lon

210 One candidate for the development of a subunit vaccine is the Y. pestis virulence (V) antigen,

211 of a trivalent P2-VP8 (P[4], P[6], and P[8]) subunit vaccine is underway at three sites in South Afri

212 study reveal that an intrinsic limitation of subunit vaccines is their artificially exposed immunodom

213 om adults who received a dose of inactivated subunit vaccine (ISV) targeting monovalent 2009 pandemic

214 alization activity; however, like many other subunit vaccines, its efficacy is limited.

215 ation of PIKA with a poorly immunogenic H5N1 subunit vaccine led to antigen sparing and quantitative

216 vaccines in immunocompromised individuals, a subunit vaccine may be an appropriate alternative.

217 Our results suggest that AMA1 subunit vaccines may be highly effective when presented

218 nduced by Vi Ag, and targeting non-Vi Ags as subunit vaccines may offer an attractive strategy to aug

219 Thus, protein subunit vaccines may prime a unique subset of differenti

220 An effective subunit vaccine must traffic to lymph nodes (LNs), activ

221 Effective subunit vaccines must elicit strong CD4(+) T cell respon

222 Synthetic subunit vaccines need to induce CD8(+) cytotoxic T cell

223 Peptide or protein-based subunit vaccines offer potential as safe and effective g

224 Because nonreplicating subunit vaccines offer the possibility of formulation fo

225 Viral subunit vaccines often contain immunodominant non-neutra

226 e traits to create a three-component Protein Subunit vaccine on Microneedle Arrays (PSMNs) for transc

227 achinery and for engineering next-generation subunit vaccines or inhibitors against this medically im

228 Inactivated and subunit vaccines overcome some of the limitations of MLV

229 We conclude that the subunit vaccine platform represents a promising strategy

230 Typhi outer-membrane protein C- and F-based subunit vaccine (porins).

231 Most subunit vaccines primarily generate humoral immune respo

232 e oral vaccines and as "reagent strains" for subunit vaccine production in a safe and economical mann

233 results show that a receptor binding domain subunit vaccine protects against serotype variants of Bo

234 , optimal timing to boost BCG-immunity using subunit vaccines remains unclear in clinical trials.

235 Most subunit vaccines require adjuvants in order to induce pr

236 However, TAA-based subunit vaccines require potent adjuvants for therapeuti

237 Highly purified subunit vaccines require potent adjuvants in order to el

238 Malaria subunit vaccines require potent adjuvants, as they lack

239 ation with DeltagD-2 versus an adjuvanted gD subunit vaccine (rgD-2) in a primary lethal ocular murin

240 A candidate ricin subunit vaccine (RiVax) consisting of a recombinant atte

241 This is the first subunit vaccine shown to protect mice against infection,

242 A target of subunit vaccine strategies is the poxvirus protein A33,

243 uding a recombinant CS6 subunit protein in a subunit vaccine strategy against ETEC.

244 No subunit vaccine strategy alone has generated demonstrabl

245 and associated pathogenesis and an effective subunit vaccine strategy appears achievable.

246 In subunit vaccines, strong CD8(+) T-cell responses are des

247 ance: Several herpes simplex virus 2 (HSV-2) subunit vaccine studies have been conducted in human sub

248 However, this and other subunit vaccines, such as virus-vectored thrombospondin-

249 DNA or viruses, live attenuated pathogens or subunit vaccines targeted and enhanced using adjuvants.

250 t interest in the development of Ab-inducing subunit vaccines targeting infections, including HIV, ma

251 The best candidate is a subunit vaccine termed RTS,S but this provides only part

252 ion model provides a platform for systematic subunit vaccine testing against visceral leishmaniasis.

253 idate antigen for inclusion in a multivalent subunit vaccine that attempts to block HSV-2 immune evas

254 Immunization of Hjv(-/-) mice with a subunit vaccine that blocks Y. pestis type III secretion

255 rs and bind complement, and a glycoprotein D subunit vaccine that elicits neutralizing but not Fc rec

256 We designed an amebiasis subunit vaccine that is constructed by using four peptid

257 solates into hybrid Coa and vWbp proteins, a subunit vaccine that provided protection against challen

258 Subunit vaccines that combine peptide or protein Ags wit

259 y and has moved from whole microorganisms to subunit vaccines that contain only their antigenic prote

260 here is much interest in rationally designed subunit vaccines that direct the antibody response to pr

261 These results support efforts to develop subunit vaccines that effectively elicit high levels of

262 exists, much effort is currently focused on subunit vaccines that elicit CD8 T cell responses direct

263 studies provide the basis for development of subunit vaccines that induce neutralizing antibodies and

264 studies provide the basis for development of subunit vaccines that induce neutralizing antibodies, as

265 fficient discrete T-cell antigens to develop subunit vaccines that produce sterile immunity.

266 cells affect the topical/mucosal delivery of subunit vaccines that stimulate the ocular mucosal immun

267 Here we review polysaccharide-conjugate and subunit vaccines that were designed to prevent S. aureus

268 f microneedle delivery of licensed influenza subunit vaccines, that could be beneficial in increasing

269 In contrast to protein subunit vaccines, there is limited manufacturing experti

270 We determined whether a subunit vaccine to a portion of PfEMP1 could induce prot

271 accination against RSV and influenza using a subunit vaccine to enhance immunity and neutralizing ant

272 uggest continuing the development of an HgbA subunit vaccine to prevent chancroid.

273 ex virus type 2 (HSV-2) glycoprotein D (gD2) subunit vaccine to prevent genital herpes.

274 ghly effective, and broad-spectrum RBD-based subunit vaccine to prevent MERS-CoV infection.

275 n experimental trivalent (gC2, gD2, and gE2) subunit vaccine to protect against nHSV.

276 ned if the ML0276 protein could be used in a subunit vaccine to provide protection against experiment

277 uggesting that it could serve as a potential subunit vaccine to provide variant cross-specific immuni

278 uide the rational design of highly effective subunit vaccines to combat MERS-CoV and other life-threa

279 The development of protein subunit vaccines to combat some of the world's deadliest

280 y for the design of unique defined-structure subunit vaccines to confer comprehensive protection via

281 The first subunit vaccines to enter clinical trails were safe and

282 general application to a spectrum of protein subunit vaccines to increase immunogenicity without the

283 hat is important for the development of p.o. subunit vaccines to target Chlamydia and possibly other

284 However, many subunit vaccines under development fail to generate robu

285 s-specific epitopes, our data suggest that a subunit vaccine using the variola virus homologues might

286 to significantly improve humoral immunity to subunit vaccines using a clinical adjuvant.

287 We describe the synthesis of a novel subunit vaccine via native chemical ligation.

288 nses that are unparalleled by a glycoprotein subunit vaccine vis-a-vis Ab persistence and host protec

289 A Hendra virus attachment (G) glycoprotein subunit vaccine was tested in nonhuman primates to asses

290 In this study, HZ/su adjuvanted subunit vaccine was well tolerated and more immunogenic

291 To improve the efficacy of this subunit vaccine, we identified a nonneutralizing epitope

292 une correlates of adjuvanticity to influenza subunit vaccine, we investigated the gene signatures ind

293 ination with adjuvants as well as adjuvanted subunit vaccines were successful in the induction of NAb

294 Specifically, well-characterized subunit vaccines, which are designed to generate antitum

295 e of vaccine delivery and by using a protein subunit vaccine with a potent adjuvant.

296 , sera from individuals vaccinated with H5N1 subunit vaccine with moderate anti-H5N1 neutralizing ant

297 light the importance of properly formulating subunit vaccines with effective adjuvants for use agains

298 h live, attenuated (nonpigmented) strains or subunit vaccines with F1 (Caf1) antigen is considered ef

299 re, many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for

300 s to determine whether adding gC-2 to a gD-2 subunit vaccine would improve protection by producing an